Back
Impleads Breast Cancer Patient in Case on Patented Drug Pricing
The on Friday allowed a 49-year-old breast cancer patient from Malappuram to be impleaded as an additional respondent in a petition examining the exorbitant pricing of life-saving patented drugs, Ribociclib and Abemaciclib. Justice Harisankar V. Menon, presiding over the matter, observed that the court is actively seeking a resolution and indicated that if the patented drugs cannot be substituted with a cheaper alternative, it may consider directing the central government to intervene under the Patents Act.
The case, originally filed in by a breast cancer patient from Ernakulam who subsequently succumbed to the disease, was converted into a proceeding by the court to address the larger public interest. The petition has now gained urgency following a request from the for expeditious disposal. The court has fixed for final arguments, directing key expert institutions to file affidavits on the of the drugs in question.
Background: A Lifeline Cut Short
The original petitioner had challenged the prohibitive costs of patented breast cancer medications, arguing that the prices placed an unbearable burden on patients. After her death, the court decided to continue the case , recognizing that the issue transcended individual interests and implicated the . The petition invokes Sections 83, 92, and 100 of the , which provide for general principles governing patents, , and government use of patented inventions in cases of extreme necessity.
Section 92 empowers the government to grant compulsory licenses for patented drugs when the reasonable requirements of the public are not met or when the drug is not available at a reasonably affordable price. Section 100 authorizes the government to requisition life-saving medicines for its own purposes, including for supply to government hospitals. The court’s exploration of these provisions signals a potential shift toward greater state intervention in pharmaceutical pricing.
The Drug Dilemma: Palbociclib as a Substitute
During the hearing, the court impleaded the , , the , and the to obtain expert opinions on whether Palbociclib—a cheaper, locally manufactured drug no longer under patent—can be used as a substitute for the patented Ribociclib and Abemaciclib.
The filed an affidavit stating that the question of is a clinical decision for treating oncologists and that the is not in a position to opine on the matter based solely on regulatory approval records. This response has left the court without a definitive answer, prompting it to seek independent expert evaluations from the impleaded cancer institutes.
emphasized that the Drug Controller’s affidavit failed to conclusively address whether Palbociclib could serve as a substitute. The court recorded this concern, noting that the affidavit did not provide a clear position on interchangeability.
Court’s Oral Observations and Potential Directions
During the proceedings, Justice Menon orally remarked, “We will find a solution… The only question is whether this is a substitute or not. Suppose it is not a substitute, I may, perhaps, issue a direction to the central government.” This statement signals the court’s willingness to invoke its constitutional powers under and the Patents Act to compel the government to take action, whether through , price capping, or direct procurement of affordable alternatives.
The court also directed to liaise with the impleaded expert institutions to ensure their affidavits are submitted by the next hearing. The urgency is underscored by the Supreme Court’s request, made on , in a related writ petition, urging the to dispose of the matter without delay.
Legal Implications: Patent Law Meets Public Health
This case represents a critical intersection of patent law and public health. The Patents Act allows for under Section 92, but its invocation is rare and often mired in procedural complexities. If the court finds that Palbociclib is a viable substitute, it could pave the way for a broader policy shift, encouraging the use of in lieu of expensive patented drugs. Conversely, if no substitute exists, the court may direct the government to exercise its powers under Section 100 to requisition Ribociclib and Abemaciclib at reasonable prices.
The involvement of the Supreme Court adds a layer of judicial oversight, reinforcing the principle that access to affordable medicines is a facet of the under . The outcome could set a precedent for similar challenges against high-priced patented drugs, particularly for cancer and rare diseases.
Impact on Legal Practice and Healthcare
For legal practitioners, this case highlights the growing in healthcare policy. The court’s willingness to implead expert bodies and seek scientific opinions underscores the need for interdisciplinary approaches in . Lawyers specializing in intellectual property and constitutional law should carefully monitor the hearing, as the court’s final order may clarify the scope of judicial power in compelling state action on drug pricing.
Healthcare providers and patient advocacy groups will be watching closely. If the court orders the government to procure Palbociclib as a substitute, it could reduce treatment costs for breast cancer patients significantly. However, oncologists caution that is not guaranteed; individual patient responses to different drugs may vary, necessitating a case-by-case evaluation. The court has acknowledged this complexity and is seeking expert input before making any sweeping directive.
Conclusion: A Decisive Hearing Ahead
As the case moves toward final arguments on , all eyes are on the expert affidavits from the National Cancer Institute, Chittaranjan National Cancer Institute, and the Regional Cancer Centre, Thiruvananthapuram. Their clinical opinions will be pivotal in determining whether Palbociclib can replace Ribociclib and Abemaciclib. The court’s earlier observation that it may issue a direction to the central government if no substitute exists signals a potential landmark ruling on and government use of patented drugs.
For the impleaded patient and countless others facing similar battles, the ’s proactive stance offers a glimmer of hope. The case not only challenges the exorbitant pricing of essential medicines but also reaffirms the judiciary’s role as a guardian of fundamental rights in the face of market failures.
